Enlivex (ENLV) Income from Continuing Operations (2014 - 2025)
Enlivex (ENLV) posted quarterly Income from Continuing Operations of 4891000.0 for Q4 2025, down 5.23% year-over-year from 5160809.99 in Q4 2024, and down 44.15% quarter-over-quarter from 3393000.0 in Q3 2025.
Enlivex (ENLV) Income from Continuing Operations (2014 - 2025) Analysis & Trends
Enlivex's Income from Continuing Operations history runs 12 years deep, the most recent figure standing at 4891000.0 for Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 5.23% year-over-year to 4891000.0; the TTM figure through Dec 2025 stood at 15822000.0 (up 9.52% YoY), while the FY2025 annual figure was 1235528000.0, up 10787.03% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 4891000.0, down from 3393000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 2055000.0 in Q2 2021, with the low at 12655000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 4656500.0 (2024), against an average of 5197450.0.
- The sharpest annual moves came in 2021 and 2022: Income from Continuing Operations soared 277.53% in 2021, then tumbled 787.28% in 2022.
- Enlivex's Income from Continuing Operations stood at 8212000.0 in 2021, then declined by 3.04% to 8462000.0 in 2022, then sank by 49.55% to 12655000.0 in 2023, then soared by 63.27% to 4648000.0 in 2024, then retreated by 5.23% to 4891000.0 in 2025.
- Business Quant data shows ENLV's Income from Continuing Operations at 4891000.0 in Q4 2025, 3393000.0 in Q3 2025, and 3639000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Enlivex | 4.58 Mn | -1.17 Mn | - | -5.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.89 Mn |
| Sep 30, 2025 | -3.39 Mn |
| Jun 30, 2025 | -3.64 Mn |
| Mar 31, 2025 | -3.90 Mn |
| Dec 31, 2024 | -4.65 Mn |
| Sep 30, 2024 | -4.24 Mn |
| Jun 30, 2024 | -3.93 Mn |
| Mar 31, 2024 | -4.67 Mn |
| Dec 31, 2023 | -12.66 Mn |
| Sep 30, 2023 | -4.64 Mn |
| Jun 30, 2023 | -6.42 Mn |
| Mar 31, 2023 | -7.25 Mn |
| Dec 31, 2022 | -8.46 Mn |
| Sep 30, 2022 | -5.89 Mn |
| Jun 30, 2022 | -10.83 Mn |
| Mar 31, 2022 | -6.41 Mn |
| Dec 31, 2021 | -8.21 Mn |
| Sep 30, 2021 | 857,000.00 |
| Jun 30, 2021 | 2.06 Mn |
| Mar 31, 2021 | -2.79 Mn |